scispace - formally typeset
S

Soumya Swaminathan

Researcher at Indian Council of Medical Research

Publications -  370
Citations -  78067

Soumya Swaminathan is an academic researcher from Indian Council of Medical Research. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 69, co-authored 353 publications receiving 61963 citations. Previous affiliations of Soumya Swaminathan include Yahoo! & Ministry of Health and Family Welfare.

Papers
More filters
Journal Article

Peak expiratory flow rate in south Indian children

TL;DR: This work measured Peak Expiratory Flow Rate (PEFR) in 345 healthy South Indian children aged 4-15 years, using the Wright mini peak flow meter, and a nomogram was constructed relating PEFR to height.
Journal ArticleDOI

Comparison of Peripheral Chemoreceptor Responses in Monozygotic and Dizygotic Twin Infants

TL;DR: The peripheral chemoresponses of infant twin pairs were determined using a single-breath hyperoxic stimulus and closer similarity of response in monozygotic twin pairs is explained by proposed high degree of heritability for the response.
Journal ArticleDOI

Priorities for cancer research in low- and middle-income countries: a global perspective

TL;DR: In this paper , the authors identified five top priorities in cancer research in low and middle-income countries based on current and projected needs: reducing the burden of patients with advanced disease; improving access and affordability, and outcomes of cancer treatment; value-based care and health economics; quality improvement and implementation research; and leveraging technology to improve cancer control.
Journal ArticleDOI

CD209 gene polymorphisms in South Indian HIV and HIV-TB patients.

TL;DR: The results suggest that -336 G/G genotype while associated with protection against HIV-1 infection the same genotype is also associated with susceptibility to HIV-TB among south Indians.
Journal ArticleDOI

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

TL;DR: Current data suggest that the standard dose of efavirenz or nevirapine is adequate in most HIV/TB co-infected adults, however, more research is needed in pediatric populations as well as to define role of drug–gene interactions.